MTOR and hepatocellular carcinoma: Interestingly, a recent study showed that SPAG5 can activate AKT/mTOR pathway in bladder urothelial carcinoma.17 SPAG5 has been reported to be an oncogene promoting proliferation in multiple cancer cells, such as hepatocellular cancer and triple‐negative breast cancer.15, 16 However, its effect on activating AKT/mTOR signalling suggested that SPAG5 might inhibit autophagy through AKT/mTOR and therefore lead to the injury of podocyte.